Through purpose-driven science, empowering medicines, and transformative advocacy we seek to improve the lives of millions. Learn more » OUR AREAS OF FOCUS Uterine Fibroids An estimated 5 million people in the U.S. suffer from symptoms of uterine fibroids. Learn more » Prostate Cancer Approximately 3 million people alive today in the U.S. have been diagnosed with prostate cancer. Learn more » MYOVANT STORIES Overcoming Stigma with Care and Community Thomasine’s journey through uterine fibroids started with pain but led to empowerment. Read Thomasine’s story PURPOSE-DRIVEN SCIENCE Myovant is developing innovative medicines that hold promise to improve people’s lives. View our pipeline TRANSFORMATIVE ADVOCACY We’re partnering with cross-sector coalitions to fight stigma, raise awareness, and empower people with information. Learn more ON TWITTER NEWS 23 Nov 2021 Myovant Sciences to Participate in the Evercore ISI 4th Annual HealthCONx Conference 8 Nov 2021 Nancy Valente, M.D. Joins Myovant Sciences’ Board of Directors 26 Oct 2021 Myovant Sciences Announces Financial Results for Second Quarter of Fiscal Year 2021 and Corporate Updates 19 Oct 2021 Myovant Sciences and Pfizer Present Data on Relugolix Combination Therapy from Studies in Uterine Fibroids and Endometriosis at the American Society for Reproductive Medicine Congress View more news EVENTS 26 Oct 2021 Myovant Sciences Q2 2021 Earnings Conference Call 15 Sep 2021 2021 Baird Global Healthcare Conference 28 Jul 2021 Myovant Sciences Q1 2021 Earnings Conference Call 17 Jun 2021 JMP Securities Life Sciences Conference View more events OUR COMPANY Our Purpose Our Leadership Our Locations OUR FOCUS The Problem Uterine Fibroids Endometriosis Prostate Cancer Infertility OUR SCIENCE Pipeline Relugolix Combination Tablet MVT-602 OUR MEDICINES OUR ADVOCACY Forward Together JOIN THE TEAM Our Culture Our Benefits Open Positions INVESTORS & MEDIA Company Overview News & Events Stock Information Financials & Filings Corporate Governance Email Alerts CONTACT US © 2021 Myovant Sciences GmbH. All rights reserved. Terms of Use Privacy Policy Cookie Policy SMS Terms & Conditions Compliance & Prescriber Information × This website uses cookies to help us give you the best experience when you visit. By using this website you consent to the use of these cookies. Find out more about how we use cookies and how to manage them by reading our Cookie Policy.

Skip to main navigation Committee Composition Audit Committee Compensation Committee Nominating and Corporate Governance Committee Terrie Curran Audit Committee Compensation Committee Mark Guinan Audit Committee Compensation Committee Adele Gulfo Nominating and Corporate Governance Committee Hiroshi Nomura Compensation Committee Myrtle Potter Nominating and Corporate Governance Committee Nancy Valente Audit Committee Nominating and Corporate Governance Committee = Chairperson = Member = Financial Expert = Lead Independent Director = Chairman of the Board TOOLKIT Print Page RSS Feeds Email Alerts Contact Search © 2021 Myovant Sciences GmbH. All rights reserved. Terms of Use Privacy Policy Cookie Policy Compliance & Prescriber Information